Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis

Volume: 7, Issue: 9, Pages: e1189 - e1196
Published: Sep 1, 2019
Abstract
BackgroundVoluntary licences are increasingly being used to expand access to patented essential medicines in low-income and middle-income countries (LMICs). Since 2014, non-exclusive voluntary licences have been issued by Gilead and Bristol-Myers Squibb for key drugs for hepatitis C virus (HCV) infection. We aimed to evaluate the effect of these licences on access to HCV treatment.MethodsWe conducted a difference-in-differences analysis,...
Paper Details
Title
Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis
Published Date
Sep 1, 2019
Volume
7
Issue
9
Pages
e1189 - e1196
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.